Prostate Cancer (CRPC) clinical trials

A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate or Darolutamide

Testing a PSMA-targeting treatment for advanced prostate cancer

This Phase 1 trial tests JANX007 in men with metastatic castration-resistant prostate cancer (cancer that keeps growing despite standard hormone treatment). It aims to find a safe dose and see whether the treatment can shrink tumors or slow progression.

JANX014 for Advanced Prostate Cancer

This study tests a new immunotherapy drug called JANX014 in men with advanced prostate cancer that has stopped responding to hormone treatments. The trial aims to find the right dose and see if this drug can help slow or stop cancer growth.

Biomarker-guided treatment for metastatic prostate cancer

This Phase 3 trial tests a prostate cancer treatment plan chosen using your tumor’s biomarker results. It aims to improve outcomes for men with metastatic prostate cancer starting first systemic treatment.

Ac-225 rosopatamab for PSMA-positive castration-resistant prostate cancer

This trial tests a radioactive drug (Ac-225 rosopatamab tetraxetan) that targets a protein called PSMA on prostate cancer cells. It is for patients whose cancer has stopped responding to hormone therapy and has spread to other parts of the body.

PSMA scan changes after starting hormone therapy for prostate cancer

This study looks at how a prostate-specific scan marker (PSMA) changes after you start or continue hormone therapy. It may help doctors better understand who responds and how quickly prostate cancer biology shifts during treatment.

CAR-T cell injection for advanced prostate cancer

This trial tests a new treatment called ACT#001 CAR-T cells, given as a local injection, for prostate cancer that has stopped responding to hormone therapy. It aims to see if this therapy is safe and can help shrink tumors.

Study of donor NK cells targeting PSMA for advanced prostate cancer

This trial tests a new treatment using natural killer cells from a healthy donor that are designed to find and attack prostate cancer cells that have a protein called PSMA. It may help men with advanced prostate cancer that has stopped responding to hormone therapy.

Study of MRT-2359 with apalutamide for prostate cancer

This trial tests a new oral drug, MRT-2359, combined with apalutamide (a standard hormone therapy) in men with a specific type of prostate cancer that has stopped responding to hormone treatment. The goal is to see if the combination can slow or stop the cancer's growth.

Aspirin plus atorvastatin for advanced, treatment-resistant prostate cancer

This trial studies whether daily aspirin and atorvastatin can slow advanced prostate cancer that has continued to grow despite hormone therapy. It may help by reducing cancer growth and inflammation, but you would need to meet several specific safety and medication rules.

Testing a targeted radiation pill for advanced prostate cancer

This Phase 1 trial tests a small-molecule treatment that carries radioactive material to help treat prostate cancer that has spread and keeps growing despite standard hormone-blocking treatment. It’s mainly looking to find a safe dose and see how well the approach works in people with limited treatment options.

Pembrolizumab plus prostate cancer drug, with or without radiation

This early-phase trial tests pembrolizumab (an immune therapy) plus an androgen-receptor–blocking prostate cancer drug, and possibly a targeted radiation treatment. It’s for men with prostate cancer that has spread and keeps worsening despite standard hormone therapy, aiming to shrink tumors and improve control of the disease.

Study radiation for early metastatic prostate cancer

This Phase 2 trial tests a radiation-focused approach for people with newly diagnosed (de novo) prostate cancer that has spread to a small number of spots, especially in bone. It aims to see how well the treatment controls the cancer while keeping side effects manageable.

Study drug for advanced prostate cancer found on PSMA scans

This trial tests [212Pb]Pb-ADVC001, a radiotherapy-like cancer treatment, in people with advanced prostate cancer that shows up on a special PSMA scan. It aims to find the safest dose and see whether it helps shrink or control metastatic cancer.

PET scan study for prostate cancer with low PSMA or neuroendocrine features

This study tests a special PET scan (fluciclovine) to see if it can better detect prostate cancer that has low PSMA levels or has changed to a neuroendocrine type. It may help find tumors that standard PSMA scans miss.

Study of MGC026 for advanced solid tumors

This trial tests a new drug called MGC026 that targets a protein called B7-H3 on cancer cells, aiming to shrink or slow different advanced solid tumors. It is an early-phase study to find the right dose and check safety.

Heat shock therapy for castration-resistant prostate cancer

This trial tests a near-infrared whole-body heat shock technique to treat prostate cancer that no longer responds to hormone therapy. It aims to see if this heat-based approach can help control the cancer.

Enhertu for prostate cancer resistant to hormone therapy

This trial is testing a drug called Enhertu for men whose prostate cancer has spread and is no longer responding to hormone treatments. You may join if you have a tumor sample that can be tested for a protein called HER2.

Ruxolitinib and Enzalutamide for Resistant Prostate Cancer

This trial tests two drugs—ruxolitinib and enzalutamide—together to see if they can help men whose prostate cancer has spread and stopped responding to abiraterone. It is for those whose cancer grew quickly on abiraterone.

New drug for advanced prostate cancer

This trial tests an experimental drug called (R)-9b for men with a specific type of advanced prostate cancer that has stopped responding to hormone therapy. The goal is to see if this drug can help control the cancer.

Prostate cancer real-world evidence registry

This study collects information from men with prostate cancer to better understand how different treatments work in real life. It follows patients when they start a new treatment and can help improve future care.

177Lu-PSMA-617 for advanced prostate cancer with bone spread

This trial tests a radioactive drug called 177Lu-PSMA-617 to see if it can help men with metastatic castration-resistant prostate cancer that has spread to the bones in a specific pattern (superscan). It's for patients who have already tried hormone therapy and have PSMA-positive tumors.

Radiation for cancer growth in prostate cancer that stopped responding to hormones

This trial tests whether giving precise radiation to a few spots of cancer growth can help control prostate cancer that has stopped responding to hormone therapy. It is for people with up to 3 growing or new spots of cancer on a special scan.

Adaptive radiation after prostate surgery to lower side effects

This trial tests a precise, short-course radiation treatment (stereotactic body radiotherapy) after prostate removal surgery that adapts to your body each day to reduce side effects. It is for people whose prostate cancer has high-risk features or a rising PSA after surgery.